RPT904 for Food Allergy

This trial explores whether a new treatment, RPT904, can help people with food allergies tolerate more of their allergen without severe reactions. RPT904 is a long-acting antibody administered through injections, potentially requiring fewer doses over time. The trial will assess if participants can consume more of their allergen, such as peanuts or milk, without significant allergic symptoms. Individuals with a documented allergy to peanuts, milk, eggs, cashews, or walnuts who experience allergic reactions during food challenges might be suitable for this study. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in allergy treatment.

The trial requires that you stop taking certain medications, such as oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers. If you are currently using these, you would need to discontinue them to participate in the study.

Research has shown that RPT904, a type of medication, is generally well-tolerated. This treatment aims to help people with food allergies by reducing their allergic reactions. In earlier studies, participants required injections only every 8 to 12 weeks, less frequently than some other treatments.

Unlike the standard of care for food allergies, which often involve strict allergen avoidance and emergency treatments like epinephrine, RPT904 offers a proactive approach. RPT904 is a subcutaneous injection that targets the underlying immune response by modulating IgE levels, which are key players in allergic reactions. Researchers are excited because this treatment has the potential to reduce the frequency and severity of allergic reactions, offering longer-lasting protection with dosing every 8 to 12 weeks. This could significantly improve the quality of life for individuals with food allergies by reducing their need for constant vigilance and emergency interventions.

Previous studies have shown promising results for RPT904 in conditions related to IgE, such as chronic spontaneous urticaria. This trial will evaluate RPT904 for food allergies, with participants receiving RPT904 every 8 weeks, every 12 weeks, or a placebo. The investigational treatment might help people with food allergies consume more of the foods they are allergic to without severe reactions. Compared to omalizumab, another treatment, RPT904 has demonstrated better results in reducing allergy symptoms. As a long-lasting antibody, RPT904 could require fewer doses over time, offering more convenience for patients. These early findings suggest that RPT904 could effectively manage food allergies.²³⁶⁷⁸